Patent intelligence · US
US 6610044
Method for genetic immunization
Method for genetic immunization
Patent details — US 6610044
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 26, 2003
- Expiration
- Aug 21, 2023
- Applicant
- Inovio AS
- Claims
- 15
- CPC classes
- A61K, A61K2039/53, A61K2039/54, A61K2039/545
Quick answer
US 6610044 (Method for genetic immunization) is held by Inovio AS. Status: expired. Granted Aug 26, 2003. Expires Aug 21, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Inovio AS
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/53, A61K2039/54, A61K2039/545, A61K2039/57, A61K39/00
More from Inovio AS
Related pharmaceutical patents in our USPTO index.
-
US 12285473
Cancer vaccines targeting MUC16 and uses thereof
granted -
US 12280108
Vaccines having an antigen and interleukin-21 as an adjuvant
granted -
US 12251561
Minimally invasive dermal electroporation device
granted -
US 12240872
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
granted -
US 12161706
Cancer vaccines targeting BORIS and uses thereof
granted -
US 12109258
Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
granted -
US 12064473
Cancer vaccines targeting Survivin and uses thereof
granted -
US 12053619
Intradermal jet injection electroporation
granted
Frequently asked questions
What is US patent 6610044?
US 6610044 (Method for genetic immunization) is held by Inovio AS. Status: expired. Granted Aug 26, 2003. Expires Aug 21, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6610044?
Inovio AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 75 pharmaceutical patents for this assignee.
When does US 6610044 expire?
Our index shows an expiration date of Aug 21, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.